Merck Presents Bladder and Kidney Cancer Data at 2026 ASCO GU Symposium
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.